Nancy D. de Ruiter
Directeur/Bestuurslid bij Leids Universitair Medisch Centrum
Oorsprong van het eerstegraads netwerk van Nancy D. de Ruiter
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Leids Universitair Medisch Centrum
Leids Universitair Medisch Centrum Hospital/Nursing ManagementHealth Services Leids Universitair Medisch Centrum provides medical research, patient care, training, and education. The firm offers fundamental medical and applied clinical research. The company was founded in 1996 and is headquartered in Leiden, the Netherlands.
7
| Private Company | Hospital/Nursing Management | 7 |
Dr. Reddy's Research & Development BV
Dr. Reddy's Research & Development BV Pharmaceuticals: MajorHealth Technology Dr. Reddy's Research & Development BV is engaged in the development and manufacture of injectable pharmaceutical products. It provides formulation, development, drug delivery, and clinical material manufacturing services to biotech and pharmaceutical companies worldwide. The company was founded by Joost J. M. Holthuis on July 20, 1995 and is headquartered in Leiden, Netherlands.
3
| Subsidiary | Pharmaceuticals: Major | 3 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Nancy D. de Ruiter via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
VERNALIS | Pharmaceuticals: Major | Chief Executive Officer | |
MERCK KGAA | Pharmaceuticals: Major | Corporate Officer/Principal | |
GALAPAGOS NV | Biotechnology | Director/Board Member | |
GSK Equity Investments Ltd.
GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | Investment Managers | Private Equity Investor | |
WESSANEN | Food: Major Diversified | Director of Finance/CFO | |
GLAXOSMITHKLINE PHARMACEUTICALS LIMITED | Pharmaceuticals: Major | Corporate Officer/Principal | |
GENMAB A/S | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
SILENCE THERAPEUTICS PLC | Miscellaneous Commercial Services | Chairman | |
FEEDBACK PLC | Packaged Software | Director/Board Member | |
The Scripps Research Institute
The Scripps Research Institute Other Consumer ServicesConsumer Services The Scripps Research Institute is a private, non-profit research organizations that performs basic biomedical research in molecular & cellular biology, chemistry, immunology and neuroscience. They receive the majority of its funding from federal agencies such as the National Institutes of Health. The organization also partners with pharmaceutical companies and is affiliated with the Scripps hospital group. The organization was founded in 1955 and is headquartered in La Jolla, California. | College/University | Corporate Officer/Principal | |
Nuon NV (Noord-Holland)
Nuon NV (Noord-Holland) Electric UtilitiesUtilities Nuon NV specialises in the generation, marketing and distribution of electricity, gas and heat. Its operations are divided into three segments such as the Distribution & Sales, Production and Trade and Grid Management. The company engages in the management and operation of energy-intensive industrial estates and street lighting activities. It has operations in the Netherlands, Belgium and Germany. Nuon is headquartered in Amsterdam, the Netherlands. | Electric Utilities | Director of Finance/CFO | |
Lonza Biologics Plc
Lonza Biologics Plc Miscellaneous Commercial ServicesCommercial Services Lonza Biologics Plc manufactures monoclonal antibodies, recombinant proteins and diagnostic monoclonal antibodies. The company was founded in 1897 and is headquartered in Slough, the United Kingdom. | Miscellaneous Commercial Services | Chief Executive Officer | |
Avantium Technologies BV
Avantium Technologies BV Miscellaneous Commercial ServicesCommercial Services Avantium Technologies BV operates as chemical technology company. It offers a breeding ground for revolutionary renewable chemistry solutions. The firm specializes in innovations and technologies for catalytic research and development services and systems. The company was founded in February 2000 and is headquartered in Amsterdam, the Netherlands | Miscellaneous Commercial Services | Director/Board Member | |
PC Associés SAS
PC Associés SAS Investment ManagersFinance IPSA SA (IPSA), a subsidiary of ACG SA, is a venture capital firm headquartered in Paris. Formerly known as Innoven Partenaires SA, the firm was founded in 1997. | Investment Managers | Chief Investment Officer | |
University of Amsterdam | College/University | Doctorate Degree Doctorate Degree | |
Linguagen Corp.
Linguagen Corp. Pharmaceuticals: OtherHealth Technology Linguagen Corp. researches and develops oral medicines. The firm also develops taste blockers and enhancers. The company was founded by Robert Margolskee in 1995 and is headquartered in Cranbury, NJ. | Pharmaceuticals: Other | Director/Board Member | |
University of Sussex | College/University | Undergraduate Degree | |
Trinity Biosystems, Inc.
Trinity Biosystems, Inc. Pharmaceuticals: MajorHealth Technology Trinity Biosystems, Inc. develops and formulates orally delivered bio-therapeutic macromolecules. It offers TriPex system, an approach to macromolecule delivery that works cooperatively with the natural physiology of the body. The system utilizes a specific and natural biological transport mechanism: a receptor-mediated transcellular transport pathway that allows passage through the mucosal epithelium and delivery of the therapeutic payload into the blood. The company was founded by Randall J. Mrsny on July 19, 2002 and is headquartered in Menlo Park, CA. | Pharmaceuticals: Major | Director/Board Member | |
University of Leiden | College/University | Doctorate Degree | |
REDPOINT BIO CORPORATION | Food: Specialty/Candy | Director/Board Member | |
Mid-Atlantic Capital Alliance | Director/Board Member | ||
MRC GLOBAL INC. | Wholesale Distributors | Director/Board Member | |
Astra Pharmaceuticals Ltd.
Astra Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Astra Pharmaceuticals Ltd. manufactures & wholesales pharmaceutical products. The company was established in 1908 and is headquartered in London, GB | Pharmaceuticals: Major | Corporate Officer/Principal | |
Shell International BV
Shell International BV Integrated OilEnergy Minerals Part of Shell Plc, Shell International BV is a Dutch company that produces oil and gases. The company is based in The Hague, Netherlands. | Integrated Oil | Director/Board Member | |
Boehringer Ingelheim BV
Boehringer Ingelheim BV Drugstore ChainsRetail Trade An international, innovative, pharmaceutical, family business Boehringer Ingelheim BV is an international, innovative pharmaceutical company that focuses on the development and marketing of new drugs that help improve the health and welfare of humans and animals. The company was established in 1945 and is headquartered in Alkmaar, the Netherlands. | Drugstore Chains | Corporate Officer/Principal | |
Commissie Voor De Milieueffectrapportage MER | Chairman | ||
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Chief Executive Officer | |
Weizmann UK
Weizmann UK Miscellaneous Commercial ServicesCommercial Services Weizmann UK is a non-profit company that operates scientific research institutes. The company is based in London, UK. The British company was founded in 1950. | Miscellaneous Commercial Services | Director/Board Member | |
Cristal Delivery BV
Cristal Delivery BV Pharmaceuticals: MajorHealth Technology Cristal Delivery BV develops and manufactures nanomedicines for therapeutic drug optimization. It offers pipeline, oncology, and inflammation programs. The company was founded by Joost J. M. Holthuis and Cristianne Rijcken in April 2011 and is headquartered in Maastricht, the Netherlands. | Pharmaceuticals: Major | Chairman | |
Staten Biotechnology BV
Staten Biotechnology BV BiotechnologyHealth Technology Staten Biotechnology BV develops drugs for the treatment of dyslipidemia. The company was founded by Paul da Silva Jardine, Daniel Rader and Alan Tall in 2014 and is headquartered in Nijmegen, the Netherlands. | Biotechnology | Director/Board Member | |
LAVA THERAPEUTICS N.V. | Biotechnology | Chief Tech/Sci/R&D Officer | |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | Biotechnology | Chairman | |
HOOKIPA PHARMA INC. | Biotechnology | Director/Board Member | |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | Pharmaceuticals: Major | Chief Executive Officer | |
Merck Healthcare | Chief Operating Officer | ||
Covicept Therapeutics, Inc.
Covicept Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Covicept Therapeutics, Inc. is a newly founded company based in California, USA. Covicept Therapeutics is focused on developing drugs to treat diseases caused by a variety of RNA viruses, including SARS-CoV-2. The American company is backed by $2.30 million in seed funding and operational support from leading European VC firm Forbion. Covicept is developing PSJ-539, a small molecule that inhibits attachment, infection, and replication of SARS-CoV-2 and other RNA viruses. PSJ-539 has shown good tolerability and high potency with excellent and high biodistribution to tissues, including the lungs, in humans, allowing for relatively low daily doses. PSJ-539 also inhibits fibrosis, a property that may be valuable for patients infected with SARS-CoV-2, both short term and long-term. The unique mechanism of action of PSJ-539 may prevent or minimize the development of resistance to vaccines and antiviral medications. The company was founded by Sam Tsimikas, Philip Gordts, and Jeffrey Esko. Sam Tsimikas has been the CEO since incorporation. | Miscellaneous Commercial Services | Director/Board Member | |
VectorY BV
VectorY BV Miscellaneous Commercial ServicesCommercial Services VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation. | Miscellaneous Commercial Services | Chief Executive Officer | |
Moonlake Immunotherapeutics AG
Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The company is based in Zug, Switzerland. The company was founded in 2021 by Arnout Ploos van Amstel, Jorge Santos da Silva, Kristian Reich. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | Pharmaceuticals: Major | Chairman | |
MOONLAKE IMMUNOTHERAPEUTICS | Pharmaceuticals: Major | Chairman | |
The Antibody Society | Chairman | ||
Sparring Bioconsult BV | Chief Executive Officer | ||
Transmark Holdings NV
Transmark Holdings NV Industrial MachineryProducer Manufacturing Transmark Holdings NV operates as a holding company with interest in distribution of valves, instrumentation and ancillary flow control equipment. The firm designs, manufactures, and services umbilical- or tether systems for use on ROVs/ROTs and cables for the power and control of installed subsea components, such as wellhead systems. The company was founded in 1956 and is headquartered in Amsterdam, the Netherlands. | Industrial Machinery | Director/Board Member |
Statistieken
Internationaal
Nederland | 16 |
Verenigde Staten | 15 |
Verenigd Koninkrijk | 12 |
Duitsland | 4 |
Frankrijk | 3 |
Sectoraal
Health Technology | 20 |
Commercial Services | 7 |
Consumer Services | 5 |
Finance | 4 |
Distribution Services | 4 |
Operationeel
Director/Board Member | 40 |
Corporate Officer/Principal | 14 |
Chairman | 10 |
Independent Dir/Board Member | 9 |
Chief Executive Officer | 9 |
Sterkste connecties
- Beurs
- Insiders
- Nancy D. de Ruiter
- Bedrijfsconnecties